Welcome to our dedicated page for Rallybio Corporation news (Ticker: $RLYB), a resource for investors and traders seeking the latest updates and insights on Rallybio Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rallybio Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rallybio Corporation's position in the market.
Rallybio (Nasdaq: RLYB) reported first quarter 2024 financial results, highlighting $94.2 million in cash as of March 31, 2024. The company is on track to start a Phase 2 trial for RLYB212 in pregnant women at higher risk of FNAIT in the second half of 2024. Rallybio also announced a collaboration with Johnson & Johnson, received an equity investment of $6.6 million, and is prioritizing its portfolio with a focus on RLYB212 and RLYB116. The company continues to progress in its clinical programs and expects to share additional data in the second half of 2024.
Rallybio (Nasdaq: RLYB) will present at the 2024 Citizens JMP Life Sciences Conference. Steve Uden, M.D., CEO, will participate in a fireside chat on May 14, 2024, at 11:30 a.m. ET in New York. The event will be live webcasted on Rallybio's website.